Clinical Applications of Single-Stranded Oligonucleotides: Current Landscape of Approved and In-Development Therapeutics

被引：61

作者：

Scharner, Juergen ^{[1
]}

Aznarez, Isabel ^{[1
]}

机构：

[1] Stoke Therapeut Inc, 45 Wiggins Ave, Bedford, MA 01730 USA

来源：

MOLECULAR THERAPY | 2021年 / 29卷 / 02期

关键词：

antisense oligonucleotides; CpG oligonucleotides; gapmer; RNase H; splicing; steric blocking;

D O I：

10.1016/j.ymthe.2020.12.022

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Single-stranded oligonucleotides have been explored as a therapeutic modality for more than 20 years. Only during the last 5 years have single-stranded oligonucleotides become a modality of choice in the fields of precision medicine and targeted therapeutics. Recently, there have been a number of development efforts involving this modality that have led to treatments for genetic diseases that were once untreatable. This review highlights key applications of single-stranded oligonucleotides that function in a sequence-dependent manner when applied to modulate precursor (pre-)mRNA splicing, gene expression, and immune pathways. These applications have been used to address diseases that range from neurological to muscular to metabolic, as well as to develop vaccines. The wide range of applications denotes the versatility of single-stranded oligonucleotides as a robust therapeutic platform. The focus of this review is centered on approved single-stranded oligonucleotide therapies and the evolution of oligonucleotide therapeutics into novel applications currently in clinical development.

引用

页码：540 / 554

页数：15

共 103 条

[1] Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy [J].

Aartsma-Rus, A ;

Bremmer-Bout, M ;

Janson, AAM ;

den Dunnen, JT ;

van Ommen, GJB ;

van Deutekom, JCT .

NEUROMUSCULAR DISORDERS, 2002, 12 :S71-S77

[2] Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues [J].

Aartsma-Rus, Annemieke ;

Straub, Volker ;

Hemmings, Robert ;

Haas, Manuel ;

Schlosser-Weber, Gabriele ;

Stoyanova-Beninska, Violeta ;

Mercuri, Eugenio ;

Muntoni, Francesco ;

Sepodes, Bruno ;

Vroom, Elizabeth ;

Balabanov, Pavel .

NUCLEIC ACID THERAPEUTICS, 2017, 27 (05) :251-259

[3] FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga [J].

Aartsma-Rus, Annemieke ;

Krieg, Arthur M. .

NUCLEIC ACID THERAPEUTICS, 2017, 27 (01) :1-+

[4] Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides [J].

Ackermann, Elizabeth J. ;

Guo, Shuling ;

Benson, Merrill D. ;

Booten, Sheri ;

Freier, Sue ;

Hughes, Steven G. ;

Kim, Tae-Won ;

Kwoh, T. Jesse ;

Matson, John ;

Norris, Dan ;

Yu, Rosie ;

Watt, Andy ;

Monia, Brett P. .

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2016, 23 (03) :148-157

[5] Comparative analysis of antisense oligonucleotide sequences for targeted skipping of Exon 51 during dystrophin Pre-mRNA splicing in human muscle [J].

Arechavala-Gomeza, V. ;

Graham, I. R. ;

Popplewell, L. J. ;

Adams, A. M. ;

Aartsma-Rus, A. ;

Kinali, M. ;

Morgan, J. E. ;

Van Deutekom, J. C. ;

Wilton, S. D. ;

Dickson, G. ;

Muntoni, F. .

HUMAN GENE THERAPY, 2007, 18 (09) :798-810

[6]

Aslesh T, 2020, METHODS MOL BIOL, V2176, P57, DOI 10.1007/978-1-0716-0771-8_4

[7] RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform [J].

Bennett, C. Frank ;

Swayze, Eric E. .

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2010, 50 :259-293

[8] Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis [J].

Benson, M. D. ;

Waddington-Cruz, M. ;

Berk, J. L. ;

Polydefkis, M. ;

Dyck, P. J. ;

Wang, A. K. ;

Plante-Bordeneuve, V. ;

Barroso, F. A. ;

Merlini, G. ;

Obici, L. ;

Scheinberg, M. ;

Brannagan, T. H., III ;

Litchy, W. J. ;

Whelan, C. ;

Drachman, B. M. ;

Adams, D. ;

Heitner, S. B. ;

Conceicao, I. ;

Schmidt, H. H. ;

Vita, G. ;

Campistol, J. M. ;

Gamez, J. ;

Gorevic, P. D. ;

Gane, E. ;

Shah, A. M. ;

Solomon, S. D. ;

Monia, B. P. ;

Hughes, S. G. ;

Kwoh, T. J. ;

McEvoy, B. W. ;

Jung, S. W. ;

Baker, B. F. ;

Ackermann, E. J. ;

Gertz, M. A. ;

Coelho, T. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :22-31

[9] Sequence motifs associated with hepatotoxicity of locked nucleic acid-modified antisense oligonucleotides [J].

Burdick, Andrew D. ;

Sciabola, Simone ;

Mantena, Srinivasa R. ;

Hollingshead, Brett D. ;

Stanton, Robert ;

Warneke, James A. ;

Zeng, Ming ;

Martsen, Elena ;

Medvedev, Alexander ;

Makarov, Sergei S. ;

Reed, Lori A. ;

Davis, John W., II ;

Whiteley, Laurence O. .

NUCLEIC ACIDS RESEARCH, 2014, 42 (08) :4882-4891

[10]

Campbell JD, 2017, METHODS MOL BIOL, V1494, P15, DOI 10.1007/978-1-4939-6445-1_2

← 1 2 3 4 5 6 7 8 9 10 →